Literature DB >> 28789393

IMP3 and p16 expression in squamous cell carcinoma of the head and neck: A comparative immunohistochemical analysis.

Marc-Oliver Riener1,2, Josef Hoegel3, Heinrich Iro4, Arndt Hartmann1, Abbas Agaimy1.   

Abstract

Expression of p16 has been established as a good surrogate marker for high-risk human papillomavirus (HPV) infection in oropharyngeal squamous cell carcinoma (OPSCC) patients, and it has been associated with an improved prognosis, irrespective of the actual HPV status. Conversely, the human insulin-like growth factor II mRNA binding protein 3 (IMP3) has been related to aggressiveness in several types of tumors. The aim of the present study was to investigate and compare p16 and IMP3 as markers of favorable and unfavorable behavior, respectively, in head and neck SCC (HNSCC), with particular reference to the HPV status. Both markers were analyzed by immunohistochemical analysis of 156 HNSCC samples originating from the oropharynx (n=81), oral cavity (n=44), larynx (n=15), hypopharynx (n=10) and nasopharynx (n=6). The HPV status was examined in a randomly selected representative subcohort (n=38) using polymerase chain reaction. Of the 156 HNSCC samples, 81 (51.9%) and 54 (34.6%) were positive for IMP3 and p16, respectively. IMP3 expression (P=0.022), p16 expression (P<0.001) and the combination of these markers (P<0.001) were significantly associated with tumor site. In particular, 69/81 (85%) OPSCC samples were positive for either one or both markers compared with 36/75 (48%) SCC samples from other sites. p16 expression was significantly associated with HPV infection (P=0.017) and a trend towards a negative association between IMP3 expression and HPV infection was observed (P=0.053). The results of the present study suggested that IMP3 and p16 are more frequently expressed in OPSCC compared with other HNSCCs. The prognostic impact of IMP3 on OPSCC remains to be investigated in a larger series with an extended follow-up period.

Entities:  

Keywords:  head and neck squamous cell carcinoma; human papillomavirus; immunohistochemistry; insulin-like growth factor II mRNA binding protein 3; p16

Year:  2017        PMID: 28789393      PMCID: PMC5529926          DOI: 10.3892/ol.2017.6352

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  38 in total

1.  Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients revealed induction of immune responses and improved OS.

Authors:  Yoshihiro Yoshitake; Daiki Fukuma; Akira Yuno; Masatoshi Hirayama; Hideki Nakayama; Takuya Tanaka; Masashi Nagata; Yasuo Takamune; Kenta Kawahara; Yoshihiro Nakagawa; Ryoji Yoshida; Akiyuki Hirosue; Hidenao Ogi; Akimitsu Hiraki; Hirofumi Jono; Akinobu Hamada; Koji Yoshida; Yasuharu Nishimura; Yusuke Nakamura; Masanori Shinohara
Journal:  Clin Cancer Res       Date:  2014-11-12       Impact factor: 12.531

Review 2.  A family of IGF-II mRNA binding proteins (IMP) involved in RNA trafficking.

Authors:  F C Nielsen; J Nielsen; J Christiansen
Journal:  Scand J Clin Lab Invest Suppl       Date:  2001

3.  Diagnostic value of immunohistochemical IMP3 expression in core needle biopsies of pancreatic ductal adenocarcinoma.

Authors:  David Lukas Wachter; Anne Schlabrakowski; Josef Hoegel; Glen Kristiansen; Arndt Hartmann; Marc-Oliver Riener
Journal:  Am J Surg Pathol       Date:  2011-06       Impact factor: 6.394

4.  Insulin-like growth factor II mRNA binding protein 3 (IMP3) expression in cervical intraepithelial neoplasia and its relationship with HIV-infection status.

Authors:  Alessandro Del Gobbo; Emanuela Bonoldi; Fulvia Milena Cribiù; Ilaria Franceschetti; Caterina Matinato; Stefano Fiori; Umberto Gianelli; Silvano Bosari
Journal:  Sex Health       Date:  2015-03       Impact factor: 2.706

5.  High-grade neuroendocrine carcinomas of the lung express K homology domain containing protein overexpressed in cancer but carcinoid tumors do not.

Authors:  Haodong Xu; Patricia A Bourne; Betsy O Spaulding; Hanlin L Wang
Journal:  Hum Pathol       Date:  2007-02-20       Impact factor: 3.466

6.  IMP3 predicts aggressive superficial urothelial carcinoma of the bladder.

Authors:  Lioudmila Sitnikova; Gary Mendese; Qin Liu; Bruce A Woda; Di Lu; Karen Dresser; Sambit Mohanty; Kenneth L Rock; Zhong Jiang
Journal:  Clin Cancer Res       Date:  2008-03-15       Impact factor: 12.531

7.  Immunohistochemical expression of IMP3 and p53 in inflammatory lesions and neoplastic lesions of the gastric mucosa.

Authors:  Johanna D Strehl; Josef Hoegel; Ines Hornicek; Arndt Hartmann; Marc-Oliver Riener
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15

8.  IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype.

Authors:  Otto Walter; Manju Prasad; Shaolei Lu; Robert M Quinlan; Kathryn L Edmiston; Ashraf Khan
Journal:  Hum Pathol       Date:  2009-08-19       Impact factor: 3.466

9.  Insulin-like growth factor II mRNA-binding protein 3 expression promotes tumor formation and invasion and predicts poor prognosis in oral squamous cell carcinoma.

Authors:  Chiao-Ying Lin; Szu-Ta Chen; Yung-Ming Jeng; Cheng-Chang Yeh; Han-Yi Chou; Yi-Ting Deng; Cheng-Chi Chang; Mark Yen-Ping Kuo
Journal:  J Oral Pathol Med       Date:  2011-02-25       Impact factor: 4.253

10.  IMP3 expression in lesions of the biliary tract: a marker for high-grade dysplasia and an independent prognostic factor in bile duct carcinomas.

Authors:  Marc-Oliver Riener; Florian R Fritzsche; Pierre-Alain Clavien; Bernhard C Pestalozzi; Nicole Probst-Hensch; Wolfram Jochum; Glen Kristiansen
Journal:  Hum Pathol       Date:  2009-05-20       Impact factor: 3.466

View more
  1 in total

1.  IMP3 Immunohistochemical Expression in Inverted Papilloma and Inverted Papilloma-Associated Sinonasal Squamous Cell Carcinoma.

Authors:  Sarah A Hakim; Nermine M Abd Raboh; Lobna S Shash
Journal:  Anal Cell Pathol (Amst)       Date:  2021-02-16       Impact factor: 2.916

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.